S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Federal student loan payments are starting again. Here's what you need to know
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
NYSE:ADCT

ADC Therapeutics (ADCT) Price Target & Analyst Ratings

$0.90
+0.07 (+8.46%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.81
$0.91
50-Day Range
$0.72
$1.68
52-Week Range
$0.68
$5.75
Volume
275,233 shs
Average Volume
312,291 shs
Market Capitalization
$68.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20

ADC Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$8.20
814.16% Upside
High Prediction$12.00
Average Prediction$8.20
Low Prediction$2.00
TypeCurrent
10/1/22 to 10/1/23
1 Month Ago
9/1/22 to 9/1/23
3 Months Ago
7/3/22 to 7/3/23
1 Year Ago
10/1/21 to 10/1/22
Consensus Rating
Hold
Hold
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.20$7.83$8.83$23.00
Predicted Upside814.16% Upside175.14% Upside112.62% Upside52.84% Upside
Get ADC Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.


ADCT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ADCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ADC Therapeutics Stock vs. The Competition

TypeADC TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.66
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside814.16% Upside869.81% Upside698.21% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/19/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$12.00+1,465.13%
9/12/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$9.00 ➝ $8.00+669.22%
8/10/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Neutral
7/11/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$5.00 ➝ $2.00+8.11%
4/24/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tazeen Ahmad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform
12/6/2022Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Quibria
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00+249.85%
(Data available from 10/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ADCT Price Target - Frequently Asked Questions

What is ADC Therapeutics's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for ADC Therapeutics stock is Hold based on the current 1 sell rating, 2 hold ratings and 3 buy ratings for ADCT. The average twelve-month price prediction for ADC Therapeutics is $8.20 with a high price target of $12.00 and a low price target of $2.00. Learn more on ADCT's analyst rating history.

Do Wall Street analysts like ADC Therapeutics more than its competitors?

Analysts like ADC Therapeutics less than other Medical companies. The consensus rating for ADC Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ADCT compares to other companies.

Is ADC Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, ADC Therapeutics's stock had 1 upgrade by analysts.

Does ADC Therapeutics's stock price have much upside?

According to analysts, ADC Therapeutics's stock has a predicted upside of 248.39% based on their 12-month price targets.

What analysts cover ADC Therapeutics?

ADC Therapeutics has been rated by HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:ADCT) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -